Treatment of Travelers’ Diarrhea: Randomized Trial Comparing Rifaximin, Rifaximin Plus Loperamide, and Loperamide Alone  Herbert L. Dupont, Zhi–Dong Jiang, Jaime Belkind–Gerson, Pablo C. Okhuysen, Charles D. Ericsson, Shi Ke, David B. Huang, Margaret W. Dupont, Javier A. Adachi, F. Javier De La Cabada, David N. Taylor, Sridvya Jaini, Francisco Martinez Sandoval  Clinical Gastroenterology and Hepatology  Volume 5, Issue 4, Pages 451-456 (April 2007) DOI: 10.1016/j.cgh.2007.02.004 Copyright © 2007 AGA Institute Terms and Conditions

Figure 1 Duration of diarrhea after initiation of treatment. TLUS, P = .0019 for median and P = .0008 for mean, comparing rifaximin-containing treatments with loperamide alone. Clinical Gastroenterology and Hepatology 2007 5, 451-456DOI: (10.1016/j.cgh.2007.02.004) Copyright © 2007 AGA Institute Terms and Conditions

Figure 2 Number of unformed stools passed during the first 72 hours of treatment. P = .0024, P = .0076, and P = .0011, comparing rifaximin, rifaximin-loperamide, and loperamide treatment groups at 0–24 hours, >24–48 hours, and >48–72 hours, respectively. A subgroup analysis showed significant differences between rifaximin and rifaximin-loperamide treatments at 0–24 hours (P = .0026) and >24–48 hours (P = .011). The mean number of total unformed stools passed during the study was lower with rifaximin-loperamide (3.99 ± 4.28) compared with rifaximin (6.23 ± 6.90; P = .004) or loperamide (6.72 ± 6.93; P = .002) alone. Clinical Gastroenterology and Hepatology 2007 5, 451-456DOI: (10.1016/j.cgh.2007.02.004) Copyright © 2007 AGA Institute Terms and Conditions

Figure 3 Patients’ global assessment of complete wellness. Patients completed a daily diary card that was reviewed clinically until wellness was achieved. A significant difference between rifaximin, rifaximin-loperamide, and loperamide treatment groups was observed at day 1 (*P = .014), day 2 (#P = .016), day 3 (‡P = .01), and day 4 (§P < .0001). A subgroup analysis showed a significant difference in the rate of global assessment of wellness between the rifaximin and rifaximin-loperamide treatment groups for day 1 (∥P = .0047) and day 2 (¶P = .0498). Clinical Gastroenterology and Hepatology 2007 5, 451-456DOI: (10.1016/j.cgh.2007.02.004) Copyright © 2007 AGA Institute Terms and Conditions